What is MOTS-c?

MOTS-c, short for “mitochondrial open reading frame of the 12S rRNA type-c,” is a small peptide encoded within mitochondrial DNA. It contains 16 amino acids and belongs to a growing group of mitochondrial-derived peptides that act as signalling molecules rather than as conventional structural proteins.

The peptide was first described in 2015 in research linking mitochondrial genetics to whole-body metabolic regulation. Experimental work suggests that MOTS-c can communicate information about cellular energy status, nutrient stress and exercise between mitochondria, the nucleus and peripheral tissues. This places it within the field of mitochondrial retrograde signalling: the process by which mitochondria influence nuclear gene expression and broader physiological adaptation.

MOTS-c is principally investigated in relation to glucose handling, insulin sensitivity, skeletal-muscle metabolism, stress resistance, inflammation, physical capacity and age-related metabolic decline. Most intervention evidence remains preclinical. Human research has mainly examined endogenous MOTS-c concentrations, exercise-induced changes and associations with metabolic or age-related phenotypes.

A peptide encoded inside mitochondrial DNA

Human mitochondrial DNA is a compact circular genome traditionally described as encoding 13 proteins required for oxidative phosphorylation, 22 transfer RNAs and two ribosomal RNAs. The discovery of small open reading frames within regions previously regarded only as ribosomal RNA sequence expanded this view. MOTS-c is encoded within the mitochondrial 12S rRNA region and is translated as a short 16-amino-acid peptide.

This origin is important because mitochondria are not only energy-producing organelles. They are dynamic sensors of nutrient availability, redox balance, inflammation and cellular stress. Mitochondrial-derived peptides appear to function as communication signals that connect these internal conditions to cellular and systemic responses.

Folate–AICAR–AMPK signalling and nuclear adaptation

A central proposed mechanism begins with effects on the folate cycle and de novo purine biosynthesis. Experimental studies report accumulation of the AMP analogue AICAR, followed by activation of AMP-activated protein kinase, or AMPK. AMPK is a conserved cellular energy sensor that responds when energy demand rises relative to supply.

Activation of AMPK favours energy-producing pathways and restrains energy-intensive biosynthesis. In metabolic tissues this can influence glucose uptake, fatty-acid oxidation, mitochondrial biogenesis-related signalling and insulin responsiveness. MOTS-c-associated effects have also been linked with SIRT1 and PGC-1α, which participate in metabolic flexibility and mitochondrial adaptation.

Under metabolic stress, MOTS-c can move from the cytoplasmic or mitochondrial environment into the nucleus. There it has been reported to interact with stress-responsive transcription factors, including NRF2-related antioxidant-response pathways, and to regulate genes involved in proteostasis, metabolism and cellular defence. This nuclear translocation distinguishes MOTS-c from a simple circulating metabolic marker and supports its proposed role as a mitochondrial-to-nuclear messenger.

Dosage & Protocol Variations

Glucose utilisation, insulin sensitivity and metabolic flexibility

The original MOTS-c experiments showed increased glucose utilisation in cultured cells and improved metabolic homeostasis in mice exposed to a high-fat diet. In these models, MOTS-c reduced diet-induced weight gain and insulin resistance without functioning as a direct substitute for insulin.

Skeletal muscle is a major site of glucose disposal and appears to be an important MOTS-c target. Preclinical findings include AMPK activation, increased GLUT4-related signalling and improved muscle insulin sensitivity. MOTS-c has also been studied in relation to hepatic lipid accumulation, adipose-tissue metabolism and the capacity to switch between carbohydrate and fat oxidation.

Human observational evidence is less consistent. Studies have reported altered circulating MOTS-c concentrations in obesity, type 2 diabetes, insulin resistance and aging, but direction and magnitude vary with sex, age, body composition, assay method and disease state. A 2024 systematic review and meta-analysis found meaningful associations between mitochondrial-derived peptide levels and metabolic phenotypes while also highlighting heterogeneity across populations.

An exercise-responsive mitochondrial signal

Exercise is one of the strongest physiological challenges to energy homeostasis. In a controlled human experiment, endogenous MOTS-c increased in skeletal muscle after cycling exercise and rose transiently in circulation during and immediately after exercise before returning toward baseline during recovery.

In mice, exogenous MOTS-c increased running performance across young, middle-aged and old animals. Muscle metabolomics and transcriptomics indicated changes in glycolysis, amino-acid metabolism, stress responses and pathways associated with metabolic adaptation. Importantly, these performance findings are preclinical and cannot be translated directly into claims of enhanced human athletic performance.

More recent mechanistic work has identified casein kinase 2, or CK2, as a direct MOTS-c-binding target involved in skeletal-muscle glucose metabolism and muscle-mass regulation. Research into a naturally occurring mitochondrial DNA variant that changes the MOTS-c sequence also suggests an interaction between genotype, physical activity, diabetes risk and sarcopenia-related traits in men.

Metabolic resilience rather than proven age reversal

Mitochondrial dysfunction, loss of metabolic flexibility, reduced stress resistance and declining skeletal-muscle capacity are recurring features of aging. MOTS-c is of interest because it connects several of these processes: mitochondrial signalling, AMPK activity, exercise adaptation, nuclear stress responses and muscle metabolism.

Circulating and muscle MOTS-c levels have been reported to decline with age in some human cohorts. In old mice, late-life intermittent treatment improved physical capacity and delayed several measures of age-associated functional decline. These findings support research into healthspan, meaning the period of life spent with preserved function, rather than proof of lifespan extension or biological age reversal.

Healthy-aging claims must therefore remain carefully qualified. No robust clinical evidence currently shows that administered MOTS-c slows human aging, extends human lifespan or treats age-related disease. The strongest evidence concerns molecular pathways and animal models, with human work still at an early observational and translational stage.

What has actually been studied in people?

Published human studies have primarily measured naturally occurring MOTS-c rather than testing an administered product. Researchers have examined exercise responses, age-related differences, obesity, insulin resistance, diabetes, cardiovascular status and the functional consequences of mitochondrial genetic variants.

The exercise study in healthy young men demonstrated that endogenous MOTS-c is dynamically regulated by physical activity. Population studies have found associations between MOTS-c levels and metabolic health, but association does not prove that raising MOTS-c would reproduce the same outcome.

As of the current scientific literature, there is no established phase 3 therapeutic programme, approved clinical indication or validated dosing standard for MOTS-c. Public trial registries should be checked for newly registered early-phase studies, but absence of mature interventional data remains a major limitation.

A limited human safety database

Because controlled human administration data are sparse, the safety profile of exogenous MOTS-c is not established. Animal studies can identify biological signals but cannot reliably predict human tolerability, immunogenicity, dose-response relationships or long-term risk.

Relevant unknowns include peptide stability, tissue distribution, renal and hepatic handling, effects on glucose in different metabolic states, interaction with exercise or medication, potential immune responses and consequences of sustained AMPK or stress-response modulation.

Research materials also require analytical confirmation of identity, purity, peptide content, sterility and endotoxin status. A purity percentage alone does not establish suitability for administration or clinical safety.

What is known about exposure?

Endogenous MOTS-c can be detected in tissues and circulation, and its levels may change rapidly in response to exercise or stress. However, validated human pharmacokinetic parameters for administered MOTS-c—including absolute bioavailability, distribution volume, metabolic clearance and terminal half-life—are not well established in peer-reviewed clinical literature.

This uncertainty is why catalogue vial content must not be interpreted as a clinical dose or dosing schedule. Preclinical dose levels are species-specific experimental exposures and are not suitable for direct conversion into human-use instructions.

PHONYX portfolio formats

Evidence behind the key claims

Frequently asked questions